Product Description
Oxiglutatione is the oxidized disulfide form of glutathione (GSH) with potential protective activity. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Oxiglutatione)
Mechanisms of Action: Free Radical Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cellectar Biosciences
Company Location: FLORHAM PARK NJ 07932
Company CEO: JAMES V. CARUSO
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Phase 2: Ovarian Cancer|Myelodysplastic Syndrome|Preleukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ND | P3 |
Completed |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2010-01-07 |
2022-03-12 |
Treatments |
|
| NOV002-C301 | P3 |
Completed |
Non-Small-Cell Lung Cancer |
2010-01-01 |
2022-07-26 |
Patient Enrollment|Primary Endpoints|Treatments |
|
| NOV002- IS21 -OC | P2 |
Completed |
Ovarian Cancer |
2008-05-01 |
2019-03-21 |
Treatments |
|
| NCT00960726 | P2 |
Withdrawn |
Myelodysplastic Syndrome|Preleukemia |
None |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|